Evidence map›Paper›PMID 22865388›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2012

Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.

Kathleen Guglielmino, Kaleena Jackson, Todd R Harris, Vincent Vu, Hua Dong, Gavin Dutrow, James E Evans, James Graham, Bethany P Cummings, Peter J Havel and 4 more

Abstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Soluble Epoxide Hydrolase and Diabetes Complications.International journal of molecular sciences · 2022
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Kathleen GuglielminoDepartment of Pharmacology, University of California, Davis, CA 95616, USA.
Kaleena Jackson
Todd R Harris
Vincent Vu
Hua Dong
Gavin Dutrow
James E Evans
James Graham
Bethany P Cummings
Peter J Havel
Nipavan Chiamvimonvat
Sanda Despa
Bruce D Hammock
Florin Despa
University of California, Davis · US

Funding

Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1987 to 2021
$50.1M
Functional Interactions of Cardiac Ion ChannelsR01HL085844 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHIAMVIMONVAT, NIPAVAN · 2007 to 2025
$7.3M
Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
Translational Study of Cardiac DysfunctionR01HL085727 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHIAMVIMONVAT, NIPAVAN, SIRISH, PADMINI · 2008 to 2022
$5.7M
HYDROLYTIC ENZYMES IN THE METABOLISM OF TOXINSR01ES002710 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1985 to 2018
$4.0M
Effects of 2wk fructose & HFCS consumption on lipid dysregulation & insulin resisR01HL091333 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAVEL, PETER J · 2008 to 2012
$2.0M
Mechanisms of cardiac Ca dysregulation and arrhythmias in ankyrin B deficiencyR01HL109501 · NHLBI · UNIVERSITY OF KENTUCKY · PI DESPA, SANDA · 2011 to 2015
$1.9M
Dietary Fructose: Hormones &TG/Lipoprotein MetabolismR01HL075675 · NHLBI · UNIVERSITY OF CALIFORNIA DAVIS · PI HAVEL, PETER J · 2004 to 2008
$1.8M
Real-time imaging of dynamic biological processes at nanometer spatial resolutionRC1GM091755 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI EVANS, JAMES E · 2009 to 2010
$999k
Surgical amelioration of type 2 diabetes: Hormones, microbiota and mitochondriaRC1DK087307 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GIULIVI, CECILIA, HAVEL, PETER J · 2009 to 2010
$985k
Effects of fish oil and alpha lipoic on the progression of insulin resistanceR21AT003645 · NCCIH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAVEL, PETER J · 2006 to 2008
$591k
Regulation of ion channels in the heartI01BX000576 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI CHIAMVIMONVAT, NIPAVAN · 2009 to 2019
–
BLRD VA I01 BX000576NCCIH NIH HHS R21-AT-003645NHLBI NIH HHS 1-R01-HL-109501NHLBI NIH HHS R01-HL-075675NHLBI NIH HHS R01 HL085727NHLBI NIH HHS R01 HL085844NHLBI NIH HHS R01-HL-091333NHLBI NIH HHS R01 HL109501NHLBI NIH HHS T32-HL-86350NIDDK NIH HHS RC1-DK-087307NIEHS NIH HHS P42-ES-004699NIEHS NIH HHS R01 ES002710NIEHS NIH HHS R01-ES-002710NIGMS NIH HHS 5-RC1-GM-091755NIGMS NIH HHS RC1 GM091755
6 · The paper itself

Abstract

Glycemic regulation improves myocardial function in diabetic patients, but finding optimal therapeutic strategies remains challenging. Recent data have shown that pharmacological inhibition of soluble epoxide hydrolase (sEH), an enzyme that decreases the endogenous levels of protective epoxyeicosatrienoic acids (EETs), improves glucose homeostasis in insulin-resistant mice. Here, we tested whether the administration of sEH inhibitors preserves cardiac myocyte structure and function in hyperglycemic rats. University of California-Davis-type 2 diabetes mellitus (UCD-T2DM) rats with nonfasting blood glucose levels in the range of 150-200 mg/dl were treated with the sEH inhibitor 1-(1-acetypiperidin-4-yl)-3-adamantanylurea (APAU) for 6 wk. Administration of APAU attenuated the progressive increase of blood glucose concentration and preserved mitochondrial structure and myofibril morphology in cardiac myocytes, as revealed by electron microscopy imaging. Fluorescence microscopy with Ca(2+) indicators also showed a 40% improvement of cardiac Ca(2+) transients in treated rats. Sarcoplasmic reticulum Ca(2+) content was decreased in both treated and untreated rats compared with control rats. However, treatment limited this reduction by 30%, suggesting that APAU may protect the intracellular Ca(2+) effector system. Using Western blot analysis on cardiac myocyte lysates, we found less downregulation of sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA), the main route of Ca(2+) reuptake in the sarcoplasmic reticulum, and lower expression of hypertrophic markers in treated versus untreated UCD-T2DM rats. In conclusion, APAU enhances the therapeutic effects of EETs, resulting in slower progression of hyperglycemia, efficient protection of myocyte structure, and reduced Ca(2+) dysregulation and SERCA remodeling in hyperglycemic rats. The results suggest that sEH/EETs may be an effective therapeutic target for cardioprotection in insulin resistance and diabetes.

Indexed as

AdamantaneAnimalsBlood GlucoseBlotting, WesternCalcium SignalingCrosses, GeneticDiabetes ComplicationsDiabetes Mellitus, Type 2Disease Models, AnimalDisease ProgressionEicosanoidsEnzyme InhibitorsEpoxide HydrolasesHeart DiseasesHypoglycemic AgentsMicroscopy, Electron, Transmission1-(1-acetyl-piperidine-4-yl)-3-adamantan-1-yl-ureaAdamantaneBlood GlucoseEicosanoidsEnzyme InhibitorsEPHX2 protein, ratEpoxide HydrolasesHypoglycemic AgentsSarcoplasmic Reticulum Calcium-Transporting ATPasesUrea

Identifiers

PMID22865388
PMCPMC3469704
OpenAlexW2148063868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.